Zanamivir

Research use only, not for human use.

Zanamivir is a hihly potent, broad-spetrum influenza viral neuraminidase (NA) inhibitor with IC50 of 0.95 nM and 2.7 nM for influenza A and B, respectively.

Zanamivir is a hihly potent, broad-spetrum influenza viral neuraminidase (NA) inhibitor with IC50 of 0.95 nM and 2.7 nM for influenza A and B, respectively; inhibits plaque formation by laboratory-passaged strains of influenza A and B viruses,IC50 ranging from 0.005 to 0.014 uM; interacts with a group of amino acids in the active site of neuraminidase, which are conserved in all influenza A and B strains. Zanamivir blocks the action of neuraminidase, which prevents the cleavage of sialic acid on the cell receptors, thus preventing release and spread of the newly formed virions.Influenza Approved(In Vitro):Zanamivir interacts with a group of amino acids in the active site of neuraminidase, which are conserved in all influenza A and B strains. Zanamivir blocks the action of neuraminidase, which prevents the cleavage of sialic acid on the cell receptors, thus preventing release and spread of the newly formed virions.(In Vivo):Zanamivir has a poor bioavailability in oral administration, with only 4–17% of the agent. Oral delivery of zanamivir has been a problem due to its strong hydrophilic nature that limits its transport across the intestinal epithelium. Permeation enhancers such as sodium cholate, hydroxypropyl β-cyclodextrin could be used with zanamivir to enhance the intestinal permeability.

Zanamivir interacts with a group of amino acids in the active site of neuraminidase, which are conserved in all influenza A and B strains. Zanamivir blocks the action of neuraminidase, which prevents the cleavage of sialic acid on the cell receptors, thus preventing release and spread of the newly formed virions.

Zanamivir has a poor bioavailability in oral administration, with only 4–17% of the agent. Oral delivery of zanamivir has been a problem due to its strong hydrophilic nature that limits its transport across the intestinal epithelium. Permeation enhancers such as sodium cholate, hydroxypropyl β-cyclodextrin could be used with zanamivir to enhance the intestinal permeability.

GG 167 | GR 121167X | Relenza

Microbiology/Virology

Influenza Virus

InfluenzaA|InfluenzaB

Infection

Influenza

139110-80-8

332.3098

C12H20N4O7

>98% (HPLC)

H2O: ≥ 33.33 mg/mL

CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@@H]([C@@H](CO)O)O)C(=O)O)N=C(N)N

D-glycero-D-galacto-Non-2-enonic acid, 5-(acetylamino)-4-[(aminoiminomethyl)amino]-2,6-anhydro-3,4,5-trideoxy-

(-20℃)

With Ice Pack

≥ 2 years